WO2005020958A3 - Aerosol delivery of curcumin - Google Patents

Aerosol delivery of curcumin Download PDF

Info

Publication number
WO2005020958A3
WO2005020958A3 PCT/US2004/027640 US2004027640W WO2005020958A3 WO 2005020958 A3 WO2005020958 A3 WO 2005020958A3 US 2004027640 W US2004027640 W US 2004027640W WO 2005020958 A3 WO2005020958 A3 WO 2005020958A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
aerosol delivery
curcumin
disclosed
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/027640
Other languages
French (fr)
Other versions
WO2005020958A2 (en
Inventor
Bharat B Aggarwal
Jack V Knight
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Priority to CA002536738A priority Critical patent/CA2536738A1/en
Priority to EP04782190A priority patent/EP1658061A2/en
Publication of WO2005020958A2 publication Critical patent/WO2005020958A2/en
Publication of WO2005020958A3 publication Critical patent/WO2005020958A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Pharmaceutical compositions suitable for aerosol delivery to a subject that include curcumin dispersed in a lipid vehicle, wherein the lipid has a transition temperature of less than about 15 °C, are disclosed. In addition, methods of treating a pathological condition in a subject that include providing one of the claimed pharmaceutical compositions and administering the composition to the subject are disclosed. For example, the pathological condition can be a hyperproliferative disease, such as cancer, an inflammatory disease, or a pulmonary disease.
PCT/US2004/027640 2003-08-26 2004-08-25 Aerosol delivery of curcumin Ceased WO2005020958A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002536738A CA2536738A1 (en) 2003-08-26 2004-08-25 Aerosol delivery of curcumin
EP04782190A EP1658061A2 (en) 2003-08-26 2004-08-25 Aerosol delivery of curcumin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49813503P 2003-08-26 2003-08-26
US60/498,135 2003-08-26

Publications (2)

Publication Number Publication Date
WO2005020958A2 WO2005020958A2 (en) 2005-03-10
WO2005020958A3 true WO2005020958A3 (en) 2005-06-30

Family

ID=34272642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/027640 Ceased WO2005020958A2 (en) 2003-08-26 2004-08-25 Aerosol delivery of curcumin

Country Status (4)

Country Link
US (1) US20050181036A1 (en)
EP (1) EP1658061A2 (en)
CA (1) CA2536738A1 (en)
WO (1) WO2005020958A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118628A1 (en) * 2001-04-05 2003-06-26 Tutuncu Nurhan Pinar Confectionery product having a salivation region and an oral comfort region
JP2005529123A (en) * 2002-04-24 2005-09-29 リサーチ　ディベロップメント　ファンデーション Synergistic effect of nuclear transcriptional regulator NF-κB inhibitor and antitumor agent
CA2489947A1 (en) * 2002-06-24 2003-12-31 Research Development Foundation Treatment of human multiple myeloma by curcumin
US7968115B2 (en) 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
US20050049299A1 (en) * 2003-08-26 2005-03-03 Aggarwal Bharat B. Selective inhibitors of stat-3 activation and uses thereof
US7462646B2 (en) 2003-08-26 2008-12-09 Research Development Foundation Osteoclastogenesis inhibitors and uses thereof
US8841326B2 (en) 2004-02-12 2014-09-23 Stc.Unm Therapeutic curcumin derivatives
US8784881B2 (en) * 2004-03-05 2014-07-22 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
US20080103213A1 (en) * 2004-03-05 2008-05-01 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of neurofibromatosis
US20070054348A1 (en) * 2005-08-30 2007-03-08 Gestwicki Jason E Methods of screening bifunctional molecules for modulated pharmacokinetic properties
FR2897755A1 (en) * 2006-02-24 2007-08-31 Greenforce Sarl Food product e.g. tapioca, flakes or granules generating method, involves cooking sufficient quantity of cleaned vegetable for permitting passage of potato masher, where passage of masher is operated in presence of curcumin type antioxidant
EP1837030A1 (en) * 2006-03-09 2007-09-26 INDENA S.p.A. Phospholipid complexes of curcumin having improved bioavailability
CN1895239B (en) * 2006-06-20 2010-05-12 中国人民解放军第二军医大学 A kind of curcumin preparation and preparation method thereof
US20080075671A1 (en) * 2006-09-22 2008-03-27 Di Mauro Thomas M Intranasally administering curcumin to the brain to treat alzheimer's disease
US8383865B2 (en) * 2007-04-17 2013-02-26 Codman & Shurtleff, Inc. Curcumin derivatives
JP2010524959A (en) * 2007-04-17 2010-07-22 コドマン・アンド・シャートレフ・インコーポレイテッド Nasal administration of curcumin in a helium gas bolus to treat Alzheimer's disease
US7745670B2 (en) * 2008-06-27 2010-06-29 Codman & Shurtleff, Inc. Curcumin-Resveratrol hybrid molecule
US20090264514A1 (en) * 2008-04-18 2009-10-22 The Research Foundation Of State University Of New York SPHINGOMYELIN SYNTHASE 2 (SMS2) DEFICIENCY ATTENUATES NFkB ACTIVATION, A POTENTIAL ANTI-ATHEROGENIC PROPERTY
US7985776B2 (en) 2008-06-27 2011-07-26 Codman & Shurtleff, Inc. Iontophoretic delivery of curcumin and curcumin analogs for the treatment of Alzheimer's Disease
US7723515B1 (en) * 2009-01-26 2010-05-25 Codman & Shurtleff, Inc. Methylene blue—curcumin analog for the treatment of alzheimer's disease
US20100286585A1 (en) 2009-01-26 2010-11-11 Codman & Shurtleff, Inc. Shunt Delivery of Curcumin
US9359196B2 (en) * 2009-09-10 2016-06-07 The Board Of Regents Of The University Of Oklahoma Antiproliferative compositions comprising curcumin analogs and methods of producing and using same
EP2501372A4 (en) * 2009-11-19 2013-04-10 Signpath Pharma Inc Intravenous infusion of curcumin and a calcium channel blocker
CA2786255A1 (en) 2009-12-31 2011-07-07 Organomed Corporation Formulations from natural products, turmeric, and aspirin
WO2011097480A1 (en) 2010-02-05 2011-08-11 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
TW201208690A (en) * 2010-08-05 2012-03-01 Indian Inst Of Technology Iit Bombay Lipid formulations
US10449193B2 (en) 2011-06-03 2019-10-22 Signpath Pharma Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
WO2012167212A2 (en) 2011-06-03 2012-12-06 Signpath Pharma Inc. Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
US10117881B2 (en) 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
US12004868B2 (en) 2011-06-03 2024-06-11 Signpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
US10238602B2 (en) 2011-06-03 2019-03-26 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
US10349884B2 (en) 2011-06-03 2019-07-16 Sighpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
DE112013004278T5 (en) 2012-08-31 2015-05-21 Signpath Pharma Inc. Curcumin-Er, a prolonged or sustained-release liposomal PLNA nanocurcum to minimize QT prolongation for cancer therapy
US20150147385A1 (en) * 2013-11-22 2015-05-28 Signpath Pharma, Inc. Intravenous synthetic curcumin (s-curcumin) for the treatment of proliferative disorders
JP6895252B2 (en) 2013-12-18 2021-06-30 サインパス ファルマ, インク.Signpath Pharma, Inc. Liposomal reduction of drug-induced inhibition of myocardial IKR channels
US9161932B1 (en) 2015-01-15 2015-10-20 Michael Smith Anesthetic and cooling mixture
JP6960855B2 (en) 2015-03-20 2021-11-05 ジョージア ステート ユニバーシティ リサーチ ファウンデーション, インク.Georgia State University Research Foundation, Inc. Compositions and Methods for Treating COPD and Other Inflammatory Conditions
DE102015008823A1 (en) * 2015-07-15 2017-01-19 Hans Muerth Use of the method and apparatus for vaporizing curcumin powder with a high performance evaporator to produce an inhalable curcumin aerosol
KR102638618B1 (en) 2016-04-27 2024-02-21 사인패스 파마 인코포레이티드 Prevention of drug-induced atrio-ventricular block
US20230310536A1 (en) * 2020-06-29 2023-10-05 Eran MAGON Water soluble curcuminoids composition for treating mouth and throat conditions
WO2025186842A1 (en) * 2024-03-08 2025-09-12 Midascare Pharmaceuticals Pvt Ltd "a curcumin based powder spray formulation"
WO2025231430A1 (en) * 2024-05-03 2025-11-06 Amalfi Bio, Inc. Compositions and methods for localized adipocyte cell death

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401777A (en) * 1991-11-14 1995-03-28 Steigerwald Arzneimittelwerk Gmbh Use of preparations of curcuma plants
WO2004091578A2 (en) * 2003-04-09 2004-10-28 Biodelivery Sciences International, Inc. Novel encochleation methods, cochleates and methods of use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523965A (en) * 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5925376C1 (en) * 1994-01-10 2001-03-20 Madalene C Y Heng Method for treating psoriasis using selected phosphorylase kinase inhibitor and additional compounds
US5958378A (en) * 1996-07-03 1999-09-28 Research Development Foundation High dose liposomal aerosol formulations containing cyclosporin A or budesonide
US5861415A (en) * 1996-07-12 1999-01-19 Sami Chemicals & Extracts, Ltd. Bioprotectant composition, method of use and extraction process of curcuminoids
US6090407A (en) * 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
TW520294B (en) * 1998-01-08 2003-02-11 Res Dev Foundation Stabilization of lipid: DNA formulations during nebulization
US6375980B1 (en) * 1998-01-08 2002-04-23 Research Development Foundation Stabilization of lipid:DNA formulations during nebulization
KR100609646B1 (en) * 1998-08-18 2006-08-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Prevention of Airway Mucus Production by Administration of EVF-R Antagonist
US20010051184A1 (en) * 1999-05-20 2001-12-13 Madalene C.Y. Heng Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases
US6673843B2 (en) * 1999-06-30 2004-01-06 Emory University Curcumin and curcuminoid inhibition of angiogenesis
US6497908B1 (en) * 1999-07-19 2002-12-24 Seiri Oshiro Turmeric-containing cooking oils and fats
US20030149113A1 (en) * 2001-10-12 2003-08-07 Caplan Michael J. Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
CA2393440A1 (en) * 1999-12-03 2001-06-07 Emory University Curcumin analogs with anti-tumor and anti-angiogenic properties
KR100799089B1 (en) * 1999-12-04 2008-01-29 리서치 디벨럽먼트 파운데이션 Deposition Enhancement Compositions of Aerosolized Drugs
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US7025992B2 (en) * 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
WO2002076427A2 (en) * 2001-03-26 2002-10-03 Thomas Jefferson University Ph sensitive liposomal drug delivery
US6673834B2 (en) * 2001-11-28 2004-01-06 Aventis Pharma Deutschland Gmbh Hydroperylene derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401777A (en) * 1991-11-14 1995-03-28 Steigerwald Arzneimittelwerk Gmbh Use of preparations of curcuma plants
WO2004091578A2 (en) * 2003-04-09 2004-10-28 Biodelivery Sciences International, Inc. Novel encochleation methods, cochleates and methods of use

Also Published As

Publication number Publication date
US20050181036A1 (en) 2005-08-18
CA2536738A1 (en) 2005-03-10
EP1658061A2 (en) 2006-05-24
WO2005020958A2 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
WO2005020958A3 (en) Aerosol delivery of curcumin
WO2008036932A3 (en) Compositions and methods comprising boswellia species
WO2007044084A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
WO2006012527A8 (en) Bivalent linkers and conjugates thereof
WO2005004818A3 (en) Heterocyclic compounds and their use as anticancer agents
WO2007138072A3 (en) Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases
WO2010078421A8 (en) Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds
WO2007070052A3 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
WO2006035237A3 (en) Methods and compositions relating to alzheimer's disease
IL189008A (en) 1-naphthalenyl-3-azabicyclo[3.1.0]hexane derivatives, process for their preparation and pharmaceutical compositions comprising them
WO2008030567A3 (en) Dry powder compound formulations and uses thereof
WO2006076620A3 (en) Bendamustine pharmaceutical compositions for lyophilisation
EP1486195A3 (en) Personal product compositions comprising structured benefit agent pre-mix or delivery vehicle and providing enhanced effect of optical modifier separate from structured benefit agent
WO2007064931A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2007002516A3 (en) Improved dosage forms for movement disorder treatment
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007112403A3 (en) Prevention and treatment of ischemia-reperfusion injury
WO2005123116A3 (en) Compositions and methods for treating or preventing oxalate-related disease
WO2007084221A9 (en) Methods and apparatus for identifying subject matter in view data
WO2008033987A3 (en) Compositions and methods to prevent cancer with cupredoxins
WO2004091645A3 (en) Composition comprising rosmarinic acid, borneol and ginsenoside
WO2008093075A3 (en) 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors
WO2005009460A3 (en) Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
WO2008011272A3 (en) Liquid monophasic lipid-soluble antioxidant compositions and processes for making the compositions
IL175220A (en) 3,5-substituted estrone derivatives, pharmaceutical compositions comprising them and their use in the manufacture of medicaments for inhibiting 17beta-hydroxysteroid dehydrogenase type i enzyme

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2536738

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004782190

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004782190

Country of ref document: EP